



European Patent granted for Intercell's synthetic adjuvant IC31™

Vienna (Austria), April 26, 2006 – Intercell (VSE, "ICLL") announced today that the European Patent Office has granted an additional key patent covering a component of Intercell's novel proprietary synthetic adjuvant IC31™. The newly issued patent (EP 1 326 634 B) specifically covers the peptide (KLK) component of IC31™. A separate patent (EP 1 296 713 B), which was issued in 2003, covers the second component of the adjuvant, an oligonucleotide (I-ODN). Both patents together provide broad patent protection for the use of IC31™ as a B- and T-cell adjuvant in vaccines.

"With the issuance of this patent, we have succeeded in establishing solid patent coverage for our innovative adjuvant, IC31™", states Alexander von Gabain, Chief Scientific Officer of Intercell. "The market demand for novel adjuvants which are safe and potent is growing. We are convinced that IC31™ will play a key role in our future vaccine development programs and those of our strategic partners, which include major players in the vaccine industry."

About IC31™

IC31™ is an adjuvant that induces T-cell and B-cell responses by using a unique synthetic formulation which combines the immunostimulating properties of an anti-microbial peptide, KLK, and an immunostimulatory oligodeoxynucleotide, ODN1a. The two component solution can be simply mixed with antigens; no conjugation is required.

Intercell currently uses IC31™ in collaborations with a number of global vaccine companies and biotech companies. These collaborations include the development of a tuberculosis vaccine in Phase I clinical trials, which has been partnered with the Danish Statens Serum Institut, and the development of a therapeutic Hepatitis B vaccine with SciGen Ltd.

About Intercell AG

Intercell AG is a biotechnology company focused on the research, development, manufacturing and future commercialization of innovative vaccines for prevention and treatment of infectious diseases for which there exists substantial unaddressed medical need. The Company develops antigens and immunizers (adjuvants) which are derived from its proprietary technology platforms and has in-house GMP manufacturing capability. Intercell has strategic partnerships with a number of global pharmaceutical companies, including sanofi pasteur, Merck&Co., Inc., SciGen Ltd., the Statens Serum Institut and the pharmaceutical division of Kirin Brewery Co. Ltd.. The Company has a broad development pipeline with a vaccine product candidate for Japanese Encephalitis in Phase III, a vaccine product candidate for Hepatitis C in Phase II, partnered vaccines for Tuberculosis and *S. aureus* which are in Phase I and five product candidates focused on infectious diseases in





pre-clinical development. Intercell is listed on the Vienna stock exchange under the symbol "ICLL".

For more information, please visit: www.intercell.com

Contact Intercell AG:

Intercell AG

Katharina Wieser

Head of Corporate Communications

Campus Vienna Biocenter 2, A-1030 Vienna

P: +43-1-20620-303

Mail to: kwieser@intercell.com

This communication expressly or implicitly contains certain forward-looking statements concerning Intercell AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Intercell AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Intercell AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.